{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T17:35:28Z","timestamp":1772386528893,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11892-022-01459-y","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T07:04:52Z","timestamp":1647932692000},"page":"203-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Implementation of Cardiometabolic Centers and Training Programs"],"prefix":"10.1007","volume":"22","author":[{"given":"Mohamad B.","family":"Taha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Cainzos-Achirica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2002-4096","authenticated-orcid":false,"given":"Kershaw V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"1459_CR1","unstructured":"National Diabetes Statistics Report, 2020 | CDC. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html. Accessed 1 Aug 2021"},{"key":"1459_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1478-7954-8-29","volume":"8","author":"JP Boyle","year":"2010","unstructured":"Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metrics. 2010;8:29. https:\/\/doi.org\/10.1186\/1478-7954-8-29.","journal-title":"Popul Health Metrics"},{"key":"1459_CR3","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMOA1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407\u201318. https:\/\/doi.org\/10.1056\/NEJMOA1608664.","journal-title":"N Engl J Med"},{"key":"1459_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMOA0706245","volume":"358","author":"P G\u00e6de","year":"2008","unstructured":"G\u00e6de P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580\u201391. https:\/\/doi.org\/10.1056\/NEJMOA0706245.","journal-title":"N Engl J Med"},{"key":"1459_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2337\/DC20-2304","volume":"44","author":"M Fang","year":"2021","unstructured":"Fang M, Selvin E. Thirty-year trends in complications in U.S. adults with newly diagnosed type 2 diabetes. Diabetes Care. 2021;44:699\u2013706. https:\/\/doi.org\/10.2337\/DC20-2304.","journal-title":"Diabetes Care"},{"key":"1459_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMOA1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633\u201344. https:\/\/doi.org\/10.1056\/NEJMOA1800256.","journal-title":"N Engl J Med"},{"key":"1459_CR7","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1001\/JAMA.2019.3471","volume":"321","author":"EW Gregg","year":"2019","unstructured":"Gregg EW, Hora I, Benoit SR. Resurgence in diabetes-related complications. JAMA. 2019;321:1867\u20138. https:\/\/doi.org\/10.1001\/JAMA.2019.3471.","journal-title":"JAMA"},{"issue":"1","key":"1459_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13098-020-00570-Y","volume":"12","author":"AF Godoy-Matos","year":"2020","unstructured":"Godoy-Matos AF, Silva J\u00fanior WS. Valerio CM (2020) NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12(1):1\u201320. https:\/\/doi.org\/10.1186\/S13098-020-00570-Y.","journal-title":"Diabetol Metab Syndr"},{"key":"1459_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1681\/ASN.2007060678","volume":"19","author":"CA Schneider","year":"2008","unstructured":"Schneider CA, Ferrannini E, DeFronzo R, et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19:182\u20137. https:\/\/doi.org\/10.1681\/ASN.2007060678.","journal-title":"J Am Soc Nephrol"},{"key":"1459_CR10","doi-asserted-by":"publisher","unstructured":"Jr DCG, Khan SS, Lloyd-Jones D, et al (2021) Bending the curve in cardiovascular disease mortality. Circulation 837\u2013851https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046501","DOI":"10.1161\/CIRCULATIONAHA.120.046501"},{"key":"1459_CR11","doi-asserted-by":"publisher","unstructured":"Virani SS, Alonso A, Aparicio HJ, et al (2021) Heart disease and stroke statistics\u20142021 Update. Circulation. E254\u2013E743. https:\/\/doi.org\/10.1161\/CIR.0000000000000950","DOI":"10.1161\/CIR.0000000000000950"},{"issue":"9","key":"1459_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41569-019-0241-y","volume":"16","author":"KV Patel","year":"2019","unstructured":"Patel KV, McGuire DK. Long-term follow-up of intensive glycaemic control in type 2 diabetes. Nat Rev Cardiol. 2019;16(9):517\u20138. https:\/\/doi.org\/10.1038\/s41569-019-0241-y.","journal-title":"Nat Rev Cardiol"},{"key":"1459_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/JAMACARDIO.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiology. 2021;6:148\u201358. https:\/\/doi.org\/10.1001\/JAMACARDIO.2020.4511.","journal-title":"JAMA Cardiology."},{"key":"1459_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"0","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;0:653\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1459_CR15","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/CIRCULATIONAHA.119.041730","volume":"140","author":"SV Arnold","year":"2019","unstructured":"Arnold SV, de Lemos JA, Rosenson RS, et al. Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease. Circulation. 2019;140:618\u201320. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.041730.","journal-title":"Circulation"},{"key":"1459_CR16","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/J.JACC.2019.01.029","volume":"73","author":"M Vaduganathan","year":"2019","unstructured":"\u2022 Vaduganathan M, Patel RB, Singh A, et al. Prescription of glucagon-like peptide-1 receptor agonists by cardiologists. J Am Coll Cardiol. 2019;73:1596\u20138. https:\/\/doi.org\/10.1016\/J.JACC.2019.01.029. Data from a multicenter healthcare system showed that cardiologists accounted for <5% of new prescriptions of GLP-1 receptor agonists.","journal-title":"J Am Coll Cardiol"},{"key":"1459_CR17","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1016\/J.JACC.2018.08.2202","volume":"72","author":"M Vaduganathan","year":"2018","unstructured":"\u2022 Vaduganathan M, Sathiyakumar V, Singh A, et al. Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling. J Am Coll Cardiol. 2018;72:3370\u20132. https:\/\/doi.org\/10.1016\/J.JACC.2018.08.2202. Approximately 5% of new prescriptions of SGLT2 inhibitors are from cardiologists in a healthcare system.","journal-title":"J Am Coll Cardiol"},{"key":"1459_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3949\/CCJM.84GR.17006","volume":"84","author":"KV Patel","year":"2017","unstructured":"Patel KV, Rocha NDA, McGuire DK. Diabetes medications and cardiovascular outcome trials: lessons learned. Cleve Clin J Med. 2017;84:759\u201367. https:\/\/doi.org\/10.3949\/CCJM.84GR.17006.","journal-title":"Cleve Clin J Med"},{"key":"1459_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJMOA1504720","volume":"13","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;13:17\u20138. https:\/\/doi.org\/10.1056\/NEJMOA1504720.","journal-title":"N Engl J Med"},{"key":"1459_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMOA1812389","volume":"380","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMOA1812389.","journal-title":"N Engl J Med"},{"key":"1459_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMOA1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357. https:\/\/doi.org\/10.1056\/NEJMOA1611925.","journal-title":"N Engl J Med"},{"key":"1459_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1056\/NEJMOA1603827","volume":"54","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;54:101. https:\/\/doi.org\/10.1056\/NEJMOA1603827.","journal-title":"N Engl J Med"},{"key":"1459_CR23","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMOA1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344. https:\/\/doi.org\/10.1056\/NEJMOA1607141.","journal-title":"N Engl J Med"},{"key":"1459_CR24","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. The Lancet. 2018;392:1519\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X.","journal-title":"The Lancet"},{"key":"1459_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394:121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"The Lancet"},{"key":"1459_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMOA2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385:896\u2013907. https:\/\/doi.org\/10.1056\/NEJMOA2108269.","journal-title":"N Engl J Med"},{"issue":"1","key":"1459_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1(1):1\u201320. https:\/\/doi.org\/10.1038\/nrdp.2015.18.","journal-title":"Nat Rev Dis Primers"},{"key":"1459_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. The Lancet. 2008;372:547\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(08)61236-2.","journal-title":"The Lancet"},{"key":"1459_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMOA1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334. https:\/\/doi.org\/10.1056\/NEJMOA1515920.","journal-title":"N Engl J Med"},{"key":"1459_CR30","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMOA1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMOA1811744.","journal-title":"N Engl J Med"},{"key":"1459_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMOA2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129\u201339. https:\/\/doi.org\/10.1056\/NEJMOA2030186.","journal-title":"N Engl J Med"},{"key":"1459_CR32","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMOA2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Eng J Med. 2020;383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMOA2024816.","journal-title":"N Eng J Med"},{"key":"1459_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet. 2019;394:131\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(19)31150-X.","journal-title":"The Lancet"},{"key":"1459_CR34","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMOA2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329. https:\/\/doi.org\/10.1056\/NEJMOA2025845.","journal-title":"N Engl J Med"},{"key":"1459_CR35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2110956","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMOA2110956.","journal-title":"N Engl J Med"},{"key":"1459_CR36","doi-asserted-by":"publisher","unstructured":"Tucker S, Bramante C, Conroy M, et al (2021) The most undertreated chronic disease: addressing obesity in primary care settings. Current Obesity Reports 2021 1\u201313https:\/\/doi.org\/10.1007\/S13679-021-00444-Y","DOI":"10.1007\/S13679-021-00444-Y"},{"key":"1459_CR37","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1056\/NEJMSA1909301","volume":"381","author":"ZJ Ward","year":"2019","unstructured":"Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381:2440\u201350. https:\/\/doi.org\/10.1056\/NEJMSA1909301.","journal-title":"N Engl J Med"},{"issue":"11","key":"1459_CR38","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37(11):1443\u201351. https:\/\/doi.org\/10.1038\/ijo.2013.120.","journal-title":"Int J Obes"},{"key":"1459_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMOA1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322. https:\/\/doi.org\/10.1056\/NEJMOA1411892.","journal-title":"N Engl J Med"},{"key":"1459_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/JAMA.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314:687\u201399. https:\/\/doi.org\/10.1001\/JAMA.2015.9676.","journal-title":"JAMA"},{"key":"1459_CR41","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet. 2017;389:1399\u2013409. https:\/\/doi.org\/10.1016\/S0140-6736(17)30069-7.","journal-title":"The Lancet"},{"key":"1459_CR42","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMOA2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMOA2032183.","journal-title":"N Engl J Med"},{"key":"1459_CR43","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021;397:971\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0.","journal-title":"The Lancet"},{"key":"1459_CR44","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/JAMA.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical Trial. JAMA. 2021;325:1403\u201313. https:\/\/doi.org\/10.1001\/JAMA.2021.1831.","journal-title":"JAMA"},{"key":"1459_CR45","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/JAMA.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 Randomized Clinical Trial. JAMA. 2021;325:1414\u201325. https:\/\/doi.org\/10.1001\/JAMA.2021.3224.","journal-title":"JAMA"},{"key":"1459_CR46","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S0140-6736(15)00075-6","volume":"386","author":"G Mingrone","year":"2015","unstructured":"Mingrone G, Panunzi S, de Gaetano A, et al. Bariatric\u2013metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. The Lancet. 2015;386:964\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(15)00075-6.","journal-title":"The Lancet"},{"key":"1459_CR47","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1056\/NEJMOA1600869\/SUPPL_FILE\/NEJMOA1600869_DISCLOSURES.PDF","volume":"376","author":"PR Schauer","year":"2017","unstructured":"Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes \u2014 5-year outcomes. N Engl J Med. 2017;376:641\u201351. https:\/\/doi.org\/10.1056\/NEJMOA1600869\/SUPPL_FILE\/NEJMOA1600869_DISCLOSURES.PDF.","journal-title":"N Engl J Med"},{"key":"1459_CR48","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/JAMA.2017.20813","volume":"319","author":"S Ikramuddin","year":"2018","unstructured":"Ikramuddin S, Korner J, Lee WJ, et al. Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the Diabetes Surgery Study. JAMA. 2018;319:266\u201378. https:\/\/doi.org\/10.1001\/JAMA.2017.20813.","journal-title":"JAMA"},{"key":"1459_CR49","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/JAMA.2019.14231","volume":"322","author":"A Aminian","year":"2019","unstructured":"Aminian A, Zajichek A, Arterburn DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019;322:1271\u201382. https:\/\/doi.org\/10.1001\/JAMA.2019.14231.","journal-title":"JAMA"},{"key":"1459_CR50","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1001\/JAMA.2018.14619","volume":"320","author":"DP Fisher","year":"2018","unstructured":"Fisher DP, Johnson E, Haneuse S, et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA. 2018;320:1570\u201382. https:\/\/doi.org\/10.1001\/JAMA.2018.14619.","journal-title":"JAMA"},{"key":"1459_CR51","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1161\/CIRCULATIONAHA.120.052386","volume":"143","author":"AG Doumouras","year":"2021","unstructured":"Doumouras AG, Wong JA, Paterson JM, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: a population-based retrospective cohort study. Circulation. 2021;143:1468\u201380. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052386.","journal-title":"Circulation"},{"key":"1459_CR52","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/APT.14327","volume":"46","author":"RJ Wong","year":"2017","unstructured":"Wong RJ, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011\u20132014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017;46:974\u201380. https:\/\/doi.org\/10.1111\/APT.14327.","journal-title":"Aliment Pharmacol Ther"},{"key":"1459_CR53","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","volume":"7","author":"N Stefan","year":"2019","unstructured":"Stefan N, H\u00e4ring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7:313\u201324. https:\/\/doi.org\/10.1016\/S2213-8587(18)30154-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1459_CR54","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet. 2016;387:679\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X.","journal-title":"The Lancet"},{"key":"1459_CR55","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMOA2028395","volume":"384","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2020;384:1113\u201324. https:\/\/doi.org\/10.1056\/NEJMOA2028395.","journal-title":"N Engl J Med"},{"issue":"9","key":"1459_CR56","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/S00125-018-4675-2","volume":"61","author":"JW Eriksson","year":"2018","unstructured":"Eriksson JW, Lundkvist P, Jansson P-A, et al. (2018) Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61(9):1923\u201334. https:\/\/doi.org\/10.1007\/S00125-018-4675-2.","journal-title":"Diabetologia"},{"key":"1459_CR57","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/J.GASTRO.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159:1290-1301.e5. https:\/\/doi.org\/10.1053\/J.GASTRO.2020.06.006.","journal-title":"Gastroenterology"},{"key":"1459_CR58","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1210\/JC.2014-2257","volume":"99","author":"RA Vigersky","year":"2014","unstructured":"Vigersky RA, Fish L, Hogan P, et al. The clinical endocrinology workforce: current status and future projections of supply and demand. J Clin Endocrinol Metab. 2014;99:3112\u201321. https:\/\/doi.org\/10.1210\/JC.2014-2257.","journal-title":"J Clin Endocrinol Metab"},{"key":"1459_CR59","doi-asserted-by":"publisher","unstructured":"Gunawan F, Partridge C, Kosiborod M, Inzucchi S (2019) SUN-149 cardiologist vs. endocrinologist encounters in patients with T2D and CVD: potential implications for glucose-lowering therapy use and education. J Endocr Soc. 3. Abstract presented at the Annual Meeting of the Endocrine Society 2019.\u00a0https:\/\/doi.org\/10.1210\/JS.2019-SUN-149","DOI":"10.1210\/JS.2019-SUN-149"},{"key":"1459_CR60","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/JAMACARDIO.2019.3796","volume":"4","author":"RB Patel","year":"2019","unstructured":"\u2022\u2022 Patel RB, Rifai MA, McEvoy JW, Vaduganathan M. Implications of specialist density for diabetes care in the United States. JAMA Cardiology. 2019;4:1174\u20135. https:\/\/doi.org\/10.1001\/JAMACARDIO.2019.3796. This study indicates that cardiologists were more represented than endocrinologists across the USA for diabetes cases, highlighting that cardiologists may play an important role in caring for patients with diabetes.","journal-title":"JAMA Cardiology."},{"key":"1459_CR61","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1016\/J.JACC.2018.09.020","volume":"72","author":"SR Das","year":"2018","unstructured":"Das SR, Everett BM, Birtcher KK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol. 2018;72:3200\u201323. https:\/\/doi.org\/10.1016\/J.JACC.2018.09.020.","journal-title":"J Am Coll Cardiol"},{"key":"1459_CR62","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/J.JACC.2020.05.037","volume":"76","author":"SR Das","year":"2020","unstructured":"Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes. J Am Coll Cardiol. 2020;76:1117. https:\/\/doi.org\/10.1016\/J.JACC.2020.05.037.","journal-title":"J Am Coll Cardiol"},{"key":"1459_CR63","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/EURHEARTJ\/EHZ486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41:255\u2013323. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHZ486.","journal-title":"Eur Heart J"},{"key":"1459_CR64","doi-asserted-by":"publisher","first-page":"E779","DOI":"10.1161\/CIR.0000000000000766","volume":"141","author":"SV Arnold","year":"2020","unstructured":"Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020;141:E779\u2013806. https:\/\/doi.org\/10.1161\/CIR.0000000000000766.","journal-title":"Circulation"},{"key":"1459_CR65","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/CIR.0000000000000230","volume":"132","author":"CS Fox","year":"2015","unstructured":"Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence. Circulation. 2015;132:691\u2013718. https:\/\/doi.org\/10.1161\/CIR.0000000000000230.","journal-title":"Circulation"},{"key":"1459_CR66","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.2337\/DC22-S010","volume":"45","author":"ADAPP Committee","year":"2022","unstructured":"Committee ADAPP. 10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142022. Diabetes Care. 2022;45:S144\u201374. https:\/\/doi.org\/10.2337\/DC22-S010.","journal-title":"Diabetes Care"},{"key":"1459_CR67","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Chang L-S, Vaduganathan M, Plutzky J, Aroda VR. Bridging the gap for patients with diabetes and cardiovascular disease through cardiometabolic collaboration. Curr Diab Rep. 2019;19(12):1\u201310. https:\/\/doi.org\/10.1007\/S11892-019-1260-0.\u00a0Discusses innovative cardiometabolic care delivery models that have the potential to improve the quality of care for patients with diabetes and cardiovascular disease.","DOI":"10.1007\/S11892-019-1260-0"},{"key":"1459_CR68","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JOP.2010.000138","volume":"6","author":"CA Bunnell","year":"2016","unstructured":"Bunnell CA, Weingart SN, Swanson S, et al. Models of multidisciplinary cancer care: physician and patient perceptions in a comprehensive cancer center. J Oncol Pract. 2016;6:283\u20138. https:\/\/doi.org\/10.1200\/JOP.2010.000138.","journal-title":"J Oncol Pract"},{"key":"1459_CR69","doi-asserted-by":"publisher","first-page":"272","DOI":"10.14797\/MDCJ-16-4-272","volume":"16","author":"K Nasir","year":"2020","unstructured":"Nasir K, Javed Z, Khan SU, et al. Big data and digital solutions: laying the foundation for cardiovascular population management CME. Methodist DeBakey Cardiovasc J. 2020;16:272. https:\/\/doi.org\/10.14797\/MDCJ-16-4-272.","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"1459_CR70","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1161\/CIRCULATIONAHA.120.051913","volume":"143","author":"BM Scirica","year":"2021","unstructured":"\u2022\u2022 Scirica BM, Cannon CP, Fisher NDL, et al. Digital care transformation. Circulation. 2021;143:507\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051913. The study used a novel remote algorithm-based cardiovascular risk management program and showed improvement in blood pressure and lipid management (more control and medication adherence.","journal-title":"Circulation"},{"key":"1459_CR71","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0003489417699420","volume":"126","author":"PA Mudd","year":"2017","unstructured":"Mudd PA, Silva AL, Callicott SS, Bauman NM. Cost analysis of a multidisciplinary aerodigestive clinic: are such clinics financially feasible? Ann Otol Rhinol Laryngol. 2017;126:401\u20136. https:\/\/doi.org\/10.1177\/0003489417699420.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"1459_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCMG.2020.12.024","author":"M Cainzos-Achirica","year":"2021","unstructured":"Cainzos-Achirica M, Patel KV, Quispe R, et al. Coronary artery calcium for the allocation of GLP-1RA for primary prevention of atherosclerotic cardiovascular disease. JACC: Cardiovasc Imaging. 2021. https:\/\/doi.org\/10.1016\/J.JCMG.2020.12.024.","journal-title":"JACC: Cardiovasc Imaging"},{"key":"1459_CR73","unstructured":"Home - Cardiometabolic Center Alliance. https:\/\/cardiometabolicalliance.org\/. Accessed 1 Aug 2021"},{"key":"1459_CR74","doi-asserted-by":"publisher","unstructured":"Thomas M, Magwire M, O\u2019Keefe JH, et al (2020) Abstract 369: Secondary risk reduction in patients with type 2 diabetes and cardiovascular disease: experience from a Cardiometabolic Center of Excellence. Circ: Cardiovasc Qual Outcomes 13. Abstract presented at the American Heart Association\u2019s Quality of Care and Outcomes Research (QCOR) 2020 Scientific Sessions.\u00a0https:\/\/doi.org\/10.1161\/HCQ.13.SUPPL_1.369","DOI":"10.1161\/HCQ.13.SUPPL_1.369"},{"key":"1459_CR75","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.amjmed.2019.02.027","volume":"132","author":"RH Eckel","year":"2019","unstructured":"\u2022\u2022 Eckel RH, Blaha MJ. Cardiometabolic medicine: a call for a new subspeciality training track in internal medicine. Am J Med. 2019;132:788\u201390. https:\/\/doi.org\/10.1016\/j.amjmed.2019.02.027. This is a proposal for a 3-year cardiometabolic medicine training program that incorporates lessons from cardiology, endocrinology, and internal medicine.","journal-title":"Am J Med"},{"key":"1459_CR76","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/XCE.0000000000000224","volume":"9","author":"C Reiter-Brennan","year":"2020","unstructured":"Reiter-Brennan C, Cainzos-Achirica M, Soroosh G, et al. Cardiometabolic medicine \u2013 the US perspective on a new subspecialty. Cardiovasc Endocrinol Metab. 2020;9:70. https:\/\/doi.org\/10.1097\/XCE.0000000000000224.","journal-title":"Cardiovasc Endocrinol Metab."},{"key":"1459_CR77","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jacc.2020.02.017","volume":"75","author":"CP McCarthy","year":"2020","unstructured":"\u2022\u2022 McCarthy CP, Chang LS, Vaduganathan M. Training the next generation of cardiometabolic specialists. J Am Coll Cardiol. 2020;75:1233\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.017. This 1-year cardiometabolic medicine fellowship proposal occurs after completing a sub-specialty fellowship and provides experience in preventive cardiology, endocrinology, and nephrology.","journal-title":"J Am Coll Cardiol"},{"key":"1459_CR78","unstructured":"A 12 month site randomized trial in adults with type 2 diabetes mellitus and history of cardiovascular disease - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03936660. Accessed 23 Sep 2021"},{"key":"1459_CR79","unstructured":"New ACC \u2018TRANSFORM CVRiD\u2019 looks to reduce CV risk in type 2 diabetes patients - American College of Cardiology. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/09\/10\/08\/42\/new-acc-transform-cvrid-looks-to-reduce-cv-risk-in-type-2-diabetes-patients. Accessed 25 Sep 2021"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-022-01459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-022-01459-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-022-01459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T05:05:09Z","timestamp":1651727109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-022-01459-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1459"],"URL":"https:\/\/doi.org\/10.1007\/s11892-022-01459-y","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"25 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, and Sanofi, speaker engagements with Novartis and Roche Diagnostics, and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr. Nasir is on the advisory board of Amgen, Novartis, Medicine Company, and his research is partly supported by the Jerold B. Katz Academy of Translational Research. No other conflicts of interest relevant to the content of this manuscript were reported by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}]}}